There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seres Therapeutics (MCRB – Research Report) and X4 Pharmaceuticals (XFOR – Research Report) with bullish sentiments.
Seres Therapeutics (MCRB)
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Seres Therapeutics today and set a price target of $16.00. The company’s shares closed last Tuesday at $6.96, close to its 52-week low of $3.84.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 21.2% and a 45.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Adverum Biotechnologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seres Therapeutics with a $20.86 average price target, which is a 190.1% upside from current levels. In a report issued on July 22, Piper Sandler also maintained a Buy rating on the stock with a $32.00 price target.
X4 Pharmaceuticals (XFOR)
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on X4 Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Tuesday at $5.66, close to its 52-week low of $5.21.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 19.0% and a 45.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
X4 Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $19.50, which is a 227.2% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.